NCT03601052View on ClinicalTrials.gov

Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 11, 2018

Primary Completion Date

June 24, 2020

Study Completion Date

June 24, 2020

Conditions

Keloid

Interventions

DRUG

Remlarsen

Intradermal injection at site of one excisional wound

DRUG

Placebo

Intradermal injection at site of second excisional wound

Trial Locations (4)

33180

Center for Clinical and Cosmetic Research, Aventura

48202

Henry Ford Health System, Detroit

60611

Northwestern University, Chicago

77845

J & S Studies, College Station

All Listed Sponsors

lead

miRagen Therapeutics, Inc.

INDUSTRY

NCT03601052 - Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids | Biotech Hunter | Biotech Hunter